Live Breaking News & Updates on Coordinator Emerging Infections
Stay updated with breaking news from Coordinator emerging infections. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New SARS-CoV-2 neutralizing antibody enters clinical phase 7thspace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from 7thspace.com Daily Mail and Mail on Sunday newspapers.
Boehringer Ingelheim: New SARS-CoV-2 Neutralizing Antibody enters Clinical Phase Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim collaborate on potential COVID-19 therapy and prevention BI 767551 (DZIF-10c) is a potent anti-SARS-CoV-2 antibody that has shown promising virus neutralizing properties in pre-clinical research Phase 1/2a clinical trials will evaluate the safety, pharmacokinetics, and antiviral activity of BI 767551 administered by intravenous infusion and by inhalation. The first patients have already been enrolled Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim today announced the initiation of Phase 1/2a clinical investigation of BI 767551, a new SARS-CoV-2 neutralizing antibody. By combining UKK, UMR and DZIF s expertise in virology, immunology and clinical investigation w ....
Credit: NIAID Cologne, Marburg, Braunschweig and Ingelheim, Germany, 18 December 2020 - Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim today announced the initiation of Phase 1/2a clinical investigation of BI 767551, a new SARS-CoV-2 neutralizing antibody. By combining UKK, UMR and DZIF s expertise in virology, immunology and clinical investigation with Boehringer Ingelheim s expertise in developing and manufacturing therapeutic antibodies, the partners developed BI 767551 as a potential new therapeutic and preventive/prophylactic option for fighting COVID-19. Virus neutralizing antibodies are expected to become an important line of defense against SARS-CoV-2, complementing vaccines and nonpharmaceutical interventions. They are being investigated as a therapy option for individuals with mild or severe infections, but also as prevention or prophylaxis in non-infected people with a high ....